Comment on

• Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

  Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A. Mangia A, et al. N Engl J Med. 2005 Jun 23;352(25):2609-17. doi: 10.1056/NEJMoa042608. N Engl J Med. 2005. PMID: 15972867 Clinical Trial.
• Novel approaches for therapy of chronic hepatitis C.

  Stauber RE, Stadlbauer V. Stauber RE, et al. J Clin Virol. 2006 Jun;36(2):87-94. doi: 10.1016/j.jcv.2006.02.003. Epub 2006 Mar 20. J Clin Virol. 2006. PMID: 16546442 Review.
• Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

  Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S. Berg T, et al. Gastroenterology. 2006 Apr;130(4):1086-97. doi: 10.1053/j.gastro.2006.02.015. Gastroenterology. 2006. PMID: 16618403 Clinical Trial.
• Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.

  Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. Jensen DM, et al. Hepatology. 2006 May;43(5):954-60. doi: 10.1002/hep.21159. Hepatology. 2006. PMID: 16628671
• Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.

  Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C; HALT-C Trial Group. Everson GT, et al. Hepatology. 2006 Dec;44(6):1675-84. doi: 10.1002/hep.21440. Hepatology. 2006. PMID: 17133499 Clinical Trial.